Drug
pixantrone dimaleate
pixantrone dimaleate is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(1)
Other(2)
Detailed Status
unknown2
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
withdrawn125%
completed125%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
withdrawnphase_3
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
NCT00551239
completedphase_2
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
NCT01086605
unknownphase_1
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105
unknownphase_2
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00069966
Clinical Trials (4)
Showing 4 of 4 trials
NCT00551239Phase 3
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
NCT01086605Phase 2
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
NCT00053105Phase 1
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00069966Phase 2
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4